TARRYTOWN, N.Y., July 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the ...

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy Regeneron plans to file by mid-2011 for ...

PHILADELPHIA — Rilonacept in patients with recurrent pericarditis led to improvements in clinical and patient-reported measures as soon as after the first injection, according to data presented at the ...

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of ...

HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ...

Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy.

May 8, 2012 — The US Food and Drug Administration (FDA) Arthritis Advisory Committee voted today against the use of rilonacept (Arcalyst, Regeneron Pharmaceuticals) to prevent gout flares. The ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced it approved rilonacept injection to treat and reduce risk for recurrent pericarditis in adults ...

HAMILTON, Bermuda, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological ...